An Overview of Innovative Techniques to Improve Cervical Cancer Screening
Although current cytomorphology-based cervical cancer screening has reduced the incidence of cervical cancer, Papsmears are associated with high false positive and false negative rates. This has spurred the search for new technologies to improve current screening. New methodologies are automation of...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2006-01-01
|
| Series: | Cellular Oncology |
| Online Access: | http://dx.doi.org/10.1155/2006/273547 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832560633767264256 |
|---|---|
| author | Esther R. Nijhuis Nathalie Reesink-Peters G. Bea A. Wisman Hans W. Nijman Jelmer van Zanden Haukeline Volders Harry Hollema Albert J. H. Suurmeijer Ed Schuuring Ate G. J. van der Zee |
| author_facet | Esther R. Nijhuis Nathalie Reesink-Peters G. Bea A. Wisman Hans W. Nijman Jelmer van Zanden Haukeline Volders Harry Hollema Albert J. H. Suurmeijer Ed Schuuring Ate G. J. van der Zee |
| author_sort | Esther R. Nijhuis |
| collection | DOAJ |
| description | Although current cytomorphology-based cervical cancer screening has reduced the incidence of cervical cancer, Papsmears
are associated with high false positive and false negative rates. This has spurred the search for new technologies to improve
current screening. New methodologies are automation of Pap-smear analysis, addition of new biological or molecular markers to
traditional cytology or using these new markers to replace the current screening method. In this overview we will summarize data
on cervical cancer epidemiology and etiology and the current cervical cancer screening approach. Available data on new screening
approaches, such as quantitative cytochemistry, detection of loss of heterozygosity (LOH) and hypermethylation analysis will
be reviewed.We discuss the potential of these approaches to replace or augment current screening. When available, data on cost–
effectiveness of certain approaches will be provided. In short, Human Papillomavirus (HPV) DNA detection stands closest to implementation
in nation-wide screening programs of all markers reviewed. However, specificity is low in women aged <35 years
and the psychological effects of knowledge of HPV positivity in absence of cervical (pre) malignant disease are important drawbacks.
In our opinion the results of large clinical trials should be awaited before proceeding to implement HPV DNA detection.
New technologies based on molecular changes associated with cervical carcinogenesis might result in comparable sensitivity,
but improved specificity. Hypermethylation analysis is likely to be more objective to identify patients with high grade squamous
intra-epithelial lesions (HSIL) or invasive cancer with a higher specificity than current cytomorphology based screening. |
| format | Article |
| id | doaj-art-e3eb6cdd104b439eaa046df6e0b957d5 |
| institution | Kabale University |
| issn | 1570-5870 1875-8606 |
| language | English |
| publishDate | 2006-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Cellular Oncology |
| spelling | doaj-art-e3eb6cdd104b439eaa046df6e0b957d52025-02-03T01:27:12ZengWileyCellular Oncology1570-58701875-86062006-01-01285-623324610.1155/2006/273547An Overview of Innovative Techniques to Improve Cervical Cancer ScreeningEsther R. Nijhuis0Nathalie Reesink-Peters1G. Bea A. Wisman2Hans W. Nijman3Jelmer van Zanden4Haukeline Volders5Harry Hollema6Albert J. H. Suurmeijer7Ed Schuuring8Ate G. J. van der Zee9Department of Gynecologic Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The NetherlandsDepartment of Gynecologic Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The NetherlandsDepartment of Gynecologic Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The NetherlandsDepartment of Gynecologic Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The NetherlandsDepartment of Gynecologic Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The NetherlandsDepartment of Gynecologic Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The NetherlandsDepartment of Pathology, University Medical Centre Groningen, University of Groningen, Groningen, The NetherlandsDepartment of Pathology, University Medical Centre Groningen, University of Groningen, Groningen, The NetherlandsDepartment of Pathology, University Medical Centre Groningen, University of Groningen, Groningen, The NetherlandsDepartment of Gynecologic Oncology, University Medical Centre Groningen, University of Groningen, Groningen, The NetherlandsAlthough current cytomorphology-based cervical cancer screening has reduced the incidence of cervical cancer, Papsmears are associated with high false positive and false negative rates. This has spurred the search for new technologies to improve current screening. New methodologies are automation of Pap-smear analysis, addition of new biological or molecular markers to traditional cytology or using these new markers to replace the current screening method. In this overview we will summarize data on cervical cancer epidemiology and etiology and the current cervical cancer screening approach. Available data on new screening approaches, such as quantitative cytochemistry, detection of loss of heterozygosity (LOH) and hypermethylation analysis will be reviewed.We discuss the potential of these approaches to replace or augment current screening. When available, data on cost– effectiveness of certain approaches will be provided. In short, Human Papillomavirus (HPV) DNA detection stands closest to implementation in nation-wide screening programs of all markers reviewed. However, specificity is low in women aged <35 years and the psychological effects of knowledge of HPV positivity in absence of cervical (pre) malignant disease are important drawbacks. In our opinion the results of large clinical trials should be awaited before proceeding to implement HPV DNA detection. New technologies based on molecular changes associated with cervical carcinogenesis might result in comparable sensitivity, but improved specificity. Hypermethylation analysis is likely to be more objective to identify patients with high grade squamous intra-epithelial lesions (HSIL) or invasive cancer with a higher specificity than current cytomorphology based screening.http://dx.doi.org/10.1155/2006/273547 |
| spellingShingle | Esther R. Nijhuis Nathalie Reesink-Peters G. Bea A. Wisman Hans W. Nijman Jelmer van Zanden Haukeline Volders Harry Hollema Albert J. H. Suurmeijer Ed Schuuring Ate G. J. van der Zee An Overview of Innovative Techniques to Improve Cervical Cancer Screening Cellular Oncology |
| title | An Overview of Innovative Techniques to Improve Cervical Cancer Screening |
| title_full | An Overview of Innovative Techniques to Improve Cervical Cancer Screening |
| title_fullStr | An Overview of Innovative Techniques to Improve Cervical Cancer Screening |
| title_full_unstemmed | An Overview of Innovative Techniques to Improve Cervical Cancer Screening |
| title_short | An Overview of Innovative Techniques to Improve Cervical Cancer Screening |
| title_sort | overview of innovative techniques to improve cervical cancer screening |
| url | http://dx.doi.org/10.1155/2006/273547 |
| work_keys_str_mv | AT estherrnijhuis anoverviewofinnovativetechniquestoimprovecervicalcancerscreening AT nathaliereesinkpeters anoverviewofinnovativetechniquestoimprovecervicalcancerscreening AT gbeaawisman anoverviewofinnovativetechniquestoimprovecervicalcancerscreening AT hanswnijman anoverviewofinnovativetechniquestoimprovecervicalcancerscreening AT jelmervanzanden anoverviewofinnovativetechniquestoimprovecervicalcancerscreening AT haukelinevolders anoverviewofinnovativetechniquestoimprovecervicalcancerscreening AT harryhollema anoverviewofinnovativetechniquestoimprovecervicalcancerscreening AT albertjhsuurmeijer anoverviewofinnovativetechniquestoimprovecervicalcancerscreening AT edschuuring anoverviewofinnovativetechniquestoimprovecervicalcancerscreening AT ategjvanderzee anoverviewofinnovativetechniquestoimprovecervicalcancerscreening AT estherrnijhuis overviewofinnovativetechniquestoimprovecervicalcancerscreening AT nathaliereesinkpeters overviewofinnovativetechniquestoimprovecervicalcancerscreening AT gbeaawisman overviewofinnovativetechniquestoimprovecervicalcancerscreening AT hanswnijman overviewofinnovativetechniquestoimprovecervicalcancerscreening AT jelmervanzanden overviewofinnovativetechniquestoimprovecervicalcancerscreening AT haukelinevolders overviewofinnovativetechniquestoimprovecervicalcancerscreening AT harryhollema overviewofinnovativetechniquestoimprovecervicalcancerscreening AT albertjhsuurmeijer overviewofinnovativetechniquestoimprovecervicalcancerscreening AT edschuuring overviewofinnovativetechniquestoimprovecervicalcancerscreening AT ategjvanderzee overviewofinnovativetechniquestoimprovecervicalcancerscreening |